Patents by Inventor Wen-Chen YEH

Wen-Chen YEH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20240141049
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: July 28, 2023
    Publication date: May 2, 2024
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • Tissue-specific Wnt signal enhancing molecules and uses thereof
    Patent number: 11958891
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in targeted tissues.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: April 16, 2024
    Assignee: Surrozen Operating, Inc.
    Inventors: Zhengjian Zhang, Jennifer Jean Brady, Aaron Ken Sato, Wen-Chen Yeh, Yang Li, Teppei Yamaguchi
  • LIVER-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES THEREOF
    Publication number: 20230374090
    Abstract: The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.
    Type: Application
    Filed: May 2, 2023
    Publication date: November 23, 2023
    Applicant: Surrozen Operating, Inc.
    Inventors: Yang LI, Zhengjian ZHANG, Randall J. BREZSKI, Leonard PRESTA, Thomas LOPEZ, Hui CHEN, Helene BARIBAULT, Wen-Chen YEH, Shengjiang TU
  • WNT surrogate molecules and uses thereof
    Patent number: 11773171
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: October 3, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Claudia Yvonne Janda, Tristan William Fowler, Helene Baribault, Kuo-Pao Lai, Liqin Xie, Randall J. Brezski, Chenggang Lu
  • WNT RECEPTOR-SPECIFIC COMPOUND AND METHOD RELATING THERETO
    Publication number: 20230295347
    Abstract: The present invention provides compounds which specifically bind to one or more Wnt receptors and methods relating thereto. In some aspects, compositions and methods for treating ocular disorders with modulators of the Wnt signaling pathway are provided. In particular, the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: December 30, 2022
    Publication date: September 21, 2023
    Inventors: Hui CHEN, Sungjin LEE, Yang LI, Wen-Chen YEH
  • Anti-LRP5/6 antibodies and methods of use
    Patent number: 11746150
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: September 5, 2023
    Assignee: Surrozen Operating, Inc.
    Inventors: Yang Li, Tom Zhiye Yuan, Aaron Ken Sato, Wen-Chen Yeh, Parthasarathy Sampathkumar
  • MODULATION OF WNT SIGNALING IN GASTROINTESTINAL DISORDERS
    Publication number: 20220195053
    Abstract: The present invention provides methods of treating gastrointestinal disorders with modulators of the WNT signaling pathway. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: March 11, 2020
    Publication date: June 23, 2022
    Applicant: Surrozen Operating Inc.
    Inventors: Yang LI, Chenggang LU, Hélène BARIBAULT, Wen-Chen YEH, Liqin XIE, I-Chieh WANG, Weixu MENG
  • MODULATION OF WNT SIGNALING IN AUDITORY DISORDERS
    Publication number: 20220175884
    Abstract: Methods of treating auditory disorders with modulators of the WNT signaling pathway are disclosed. Also provided are methods of administration and pharmaceutical compositions.
    Type: Application
    Filed: April 1, 2020
    Publication date: June 9, 2022
    Inventors: Sungjin LEE, Yang LI, Wen-Chen YEH
  • MODULATION OF WNT SIGNALLING IN OCULAR DISORDERS
    Publication number: 20220112278
    Abstract: The present invention provides methods of treating ocular disorders with modulators of the WNT signaling pathway. In particular the ocular disorders are retinopathies. Also provided are methods of dosing and pharmaceutical compositions.
    Type: Application
    Filed: February 11, 2020
    Publication date: April 14, 2022
    Inventors: Yang LI, Shengjiang TU, Sungjin LEE, Wen-Chen YEH
  • TISSUE-SPECIFIC WNT SIGNAL ENHANCING MOLECULES AND USES
    Publication number: 20210380678
    Abstract: The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.
    Type: Application
    Filed: July 9, 2019
    Publication date: December 9, 2021
    Inventors: Zhengjian ZHANG, Yang LI, Wen-Chen YEH, Tom Zhiye YUAN, Helene BARIBAULT, Kuo-Pao LAI
  • Alkyl substituted triazole compounds as agonists of the APJ Receptor
    Patent number: 11191762
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: December 7, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden, Ankit Sharma
  • Heteroaryl-substituted triazoles as APJ receptor agonists
    Patent number: 11046680
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 29, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Daniel B. Horne, Jonathan Houze, Matthew R. Kaller, Frank Kayser, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Nobuko Nishimura, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Kevin Yang, Wen-Chen Yeh
  • Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
    Patent number: 11020395
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I) (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: June 1, 2021
    Assignee: AMGEN INC.
    Inventors: Yinhong Chen, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, David J. Kopecky, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Philip Dean Ramsden
  • ANTI-FRIZZLED ANTIBODIES AND METHODS OF USE
    Publication number: 20210087280
    Abstract: The present invention provides anti-Fzd monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 25, 2021
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Chenggang LU, Parthasarathy SAMPATHKUMAR, Claudia Yvonne JANDA
  • ANTI-LRP5/6 ANTIBODIES AND METHODS OF USE
    Publication number: 20210079089
    Abstract: The present invention provides anti-LRP5/6 monoclonal antibodies and related compositions, which may be used in any of a variety of therapeutic methods for treating diseases and disorders associated with Wnt pathway signaling.
    Type: Application
    Filed: December 19, 2018
    Publication date: March 18, 2021
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Parthasarathy SAMPATHKUMAR
  • Triazole phenyl compounds as agonists of the APJ receptor
    Patent number: 10906890
    Abstract: Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: (I), (II) where the definitions of the variables are provided herein.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: February 2, 2021
    Assignee: AMGEN INC.
    Inventors: Ning Chen, Yinhong Chen, Mikkel V. Debenedetto, Paul John Dransfield, James S. Harvey, Julie Anne Heath, Jonathan Houze, Aarif Yusuf Khakoo, Su-Jen Lai, Zhihua Ma, Nobuko Nishimura, Vatee Pattaropong, Gayathri Swaminath, Wen-Chen Yeh, Charles Kreiman
  • METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING GROWTH DIFFERENTIATION FACTOR 15 (GDF-15)
    Publication number: 20200325200
    Abstract: Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes mellitus, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Application
    Filed: July 1, 2020
    Publication date: October 15, 2020
    Applicant: AMGEN INC.
    Inventors: Yumei XIONG, Yang LI, Wen-Chen YEH, Bei SHAN, Jackie Zeqi SHENG
  • WNT SURROGATE MOLECULES AND USES THEREOF
    Publication number: 20200308287
    Abstract: The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.
    Type: Application
    Filed: December 19, 2018
    Publication date: October 1, 2020
    Inventors: Yang LI, Tom Zhiye YUAN, Aaron Ken SATO, Wen-Chen YEH, Claudia Yvonne JANDA, Tristan William FOWLER, Helene BARIBAULT, Kuo-Pao LAI, Liqin XIE, Randall J. BREZSKI, Chenggang LU
  • Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
    Patent number: 10752664
    Abstract: Methods of treating metabolic diseases and disorders using a GDF15 polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy.
    Type: Grant
    Filed: April 5, 2012
    Date of Patent: August 25, 2020
    Assignee: AMGEN INC.
    Inventors: YuMei Xiong, Yang Li, Wen-Chen Yeh, Bei Shan, Jackie Zeqi Sheng
  • Triazole furan compounds as agonists of the APJ receptor
    Patent number: 10736883
    Abstract: Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed.
    Type: Grant
    Filed: November 3, 2017
    Date of Patent: August 11, 2020
    Assignee: AMGEN INC.
    Inventors: Matthew Brown, Ning Chen, Xiaoqi Chen, Yinhong Chen, Alan C. Cheng, Richard V. Connors, Jeffrey Deignan, Paul John Dransfield, Xiaohui Du, Zice Fu, James S. Harvey, Julie Anne Heath, Lars V. Heumann, Jonathan Houze, Frank Kayser, Aarif Yusuf Khakoo, David j. Kopecky, Su-Jen Lai, Zhihua Ma, Julio C. Medina, Jeffrey T. Mihalic, Steven H. Olson, Vatee Pattaropong, Gayathri Swaminath, Xiaodong Wang, Malgorzata Wanska, Wen-Chen Yeh